This article is more than 5 years old. Information may no longer be current.
Nextbiotix receives 7 million euros to develop bacterial IBD therapy
Nextbiotix — a French microbiome company — announced that it received 7 million euros in series A funding to help its development of a bacteria-based treatment for inflammatory bowel disease.
The therapy is centered on the bacterium, Faecalibacterium prausnitzii, and harnessing it to bring gut microbiota back into the therapeutic equation, according to a press release.
“We are delighted to have raised a first round of financing significant enough to support our efforts in bringing a revolutionary new class of medicines, called Live Biotherapeutics, to patients,” Benjamin Hadida, Nextbiotix CEO, said in the press release.
Auriga Partners, Sofimac Innovation, cap Innov’Est, INRA and Biocodex were all involved in the series A financing.
“I am particularly proud to see Nextbiotix coming out of the ground of the longstanding relationship we have established with Auriga Partners over the last year and a half.” Hadida said in the release. “The support of our incubators Paris Biotech Santé and Wilco was also pivotal in this success. Together we have managed to assemble a very robust and complementary team of investors bringing a wide range of expertise to the table.”
Disclosures: Hadida is employed by Nextbiotix.